Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add filters








Year range
1.
Iranian Journal of Public Health. 2012; 41 (12): 76-80
in English | IMEMR | ID: emr-156028

ABSTRACT

Stress is not always a direct result of stressful conditions, but rather the way they are perceived. Thus individual variables that may be associated with perceived stress should be examined in stress studies. This study investigates the intermediary role of self-efficacy in relation with stress, glycosylated haemoglobin and health-related quality of life in patients with type2 diabetes. All women with diabetes in Yazd Diabetes Research Centre, in 2012, were considered and 80 women were selected by random sampling. They completed Shirer's self-efficacy scale questionnaire, depression, anxiety and stress scale [DASS], and ADDQ0L19 questionnaire. Then they were introduced to the lab for blood test. Data were analysed by SPSS software and stepwise regression method. Pearson correlation test results showed that the hemoglobin A1c [r = 0.35] and Quality of Life [r = -0.22] are associated with stress [P <0.05]. As so hemoglobin A1c [r = 0.83] and Quality of Life [r = 0.37] with variable of self efficacy are associated positively and significantly [P <0.05]. Results of stepwise regression also showed that self efficacy and stress scales 0.697 of variance hemoglobin A1c and 0.140 of variance of Quality of life explaining to do. The impact of stress on blood sugar and patients' health-related quality of life can be influenced by their self-efficacy; therefore it is suggested that an educational intervention is done to increase patients' self-efficacy to better cope with stress in their life

2.
Journal of Medicinal Plants. 2012; 11 (43): 19-27
in English | IMEMR | ID: emr-151855

ABSTRACT

Advanced type 2 diabetes mellitus [T2DM] needing insulin therapy is a common disease. Previous studies indicate that aloe [Aloe vera L.] leaf gel may positively affect the blood glucose and lipid levels in patients with advanced T2DM needing insulin. Evaluation of the efficacy and safety of aloe leaf gel in the treatment of type 2 diabetic patients resistant to oral synthetic anti-hyperglycemic drugs needing insulin. In this randomized double - blind placebo-controlled clinical trial with the patients aged 40-60 years, the efficacy and safety of taking aloe leaf gel [one 300 mg capsule every 12 hours for 2 months] combined with oral synthetic anti-hyperglycemic drugs in treatment of 35 patients were evaluated and compared with the placebo group [n = 35]. The aloe leaf gel lowered the blood levels of fasting glucose and glycosylated hemoglobin significantly [p = 0.041 and p = 0.023 respectively] without any significant effects on the lipid profile and liver/kidney function tests [p > 0.05] compared with placebo at the endpoint. No adverse effects were reported. The results suggest that aloe leaf gel may safely improve glycemic control in patients with advanced T2DM needing insulin

3.
Journal of Qazvin University of Medical Sciences and Health Services [The]. 2008; 12 (1): 21-26
in Persian | IMEMR | ID: emr-143417

ABSTRACT

Diabetes mellitus is the most common endocrine disorder causing micro- and macrovascular complications which could be prevented by good glycemic control. Considering many patients who become resistant to routine anti-diabetic drugs after few years, the administration of other drugs to reduce the level of glucose is an essential approach for a better glycemic control. The aim of this study was to compare the effects of fluoxetine and alprazolam added to regular anti-diabetic drugs on blood glucose in patients with type 2 diabetes. In this paralleled clinical trial, 66 uncontrolled type 2 diabetic patients referred to Yazd Diabetes Research Center were selected and received randomly either 20mg of fluoxetine or 0.5mg of alprazolam for 6 weeks. Mean FBS [fasting blood sugar], 2hpp [2 hours post-prandial glucose], HbA1c [Glycated Hemoglobin] and BMI [Body Mass Index] were measured before and after the study. Data were analyzed by t-test and paired t-test. The mean FBS, 2hpp, HbA1c and BMI were decreased after using fluoxetine by 27.5 +/- 7.5mg/dl, 47.5 +/- 10.5, 1.5 +/- 0.5% and 2.2 +/- 0.8kg/m2, respectively [P=0.001]. Also the mean FBS, 2hpp and HbA1c were decreased by 13.7 +/- 13.5mg/dl, 22.5 +/- 5.6mg/dl and 0.5 +/- 0.3% following the administration of alprazolam [P=0.001]. Similarly, the mean BMI was increased by 0.3 +/- 1.5 kg/m2 this difference was found to be statistically insignificant [P=0.35]. Both fluoxetine and alprazolam were useful for better control of blood glucose in diabetics who were free of diabetic complications nevertheless, it seems that fluoxetine is more effective than alprazolam


Subject(s)
Humans , Alprazolam , Blood Glucose/drug effects , Diabetes Mellitus, Type 2 , Treatment Outcome , Body Mass Index , Glycated Hemoglobin
4.
Journal of Shaheed Sadoughi University of Medical Sciences and Health Services. 2005; 13 (1): 3-7
in Persian | IMEMR | ID: emr-171349

ABSTRACT

Leptin is a fat tissue hormone that has 176 amino acids with a molecular weight of 16 KD. Leptin has effects on the hypothalamus and peripheral tissues resulting in decreased food absorption and increased energy consumption that finally reduces the body weight and BMI. The aim of this research was to investigate the blood levels of leptin before and after treatment with Metformin in type II diabetic patients. 25 type II diabetic patients without any previous drug treatment history were investigated. This study was a clinical trail before and after treatment with Metformin. There was no particular difference in BMI, average body weight, fat mass and free fat mass before and after treatment. Similarly, the difference in concentration levels of blood glucose, cholesterol, tri-glycerides and LDL-cholesterol before and after treatment was not statistically significant. Also, there was no difference in the average concentration of leptin and insulin before and after treatment. This result showed that although metformin decreased glucose and lipid levels during the treatment period, [1 month] it did not have an effect on leptin, Insulin and other related factors during treatment

5.
Journal of Shaheed Sadoughi University of Medical Sciences and Health Services. 2005; 13 (1): 8-11
in Persian | IMEMR | ID: emr-171350

ABSTRACT

Hyperlipidemia and diabetes are common risk factors for ischemic heart disease, which is themain cause of mortality in diabetic patients. Strict control of blood glucose and other risk factors in diabetics hasled to prevention of complications. Garlic has received particular attention for control of blood glucose anddecrease in blood lipid levels. At present, several studies have been carried out in order to prove advantages ofgarlic.In this study, effects of garsin [a derivative of garlic present in our country] on serum lipids and bloodglucose levels in diabetes mellitus type 2 patients was observed. Forty-five type 2 diabetics who hadhyperlipidemia were selected. These patients were kept on treatment with 3 tablets of Garsin / day for 4 weeks.Serum lipids and blood glucose levels were measured prior to and at the end of treatment.Relationship between sex and response to treatment in this study was meaningful, such that Gsarsin ledto decrease in LDL-C and increase in HDL in females.Therefore, Garsin can be used as an adjunct to treatment in diabetes type 2 patients withhyperlipidemia

6.
Journal of Zahedan University of Medical Sciences and Health Services. 2005; 7 (1): 9-14
in Persian | IMEMR | ID: emr-176699

ABSTRACT

Before adding metformin to oral anti diabetic drugs, only sulfonylureas were available. When sulfonylureas failed, insulin therapy had to be initiated. For this reason utilization of insulin was more than now. The purpose of this study is evaluation of success in re-initiation of oral therapy in insulin treated patients with type 2 diabetes. This study is an outcome study, we attempted reinitiation of combination oral therapy with metformin and a sulfonylurea in 32 patients who had type 2 diabetes for less than 30 years and had received less than 40U insulin for less than 10 years. Of 32 patients, reinitiation of oral therapy was successful in 20 patients and unsuccessful in 12 [P=0.014]. In 13 of 16 patients with less than 10 years diabetes duration, and in 7 of 16 patients with more than 10 years diabetes duration, re-initiation of oral therapy was successful [P=0.028]. In patients who received 10-25 u/day,%76, and in patients who received 26- 40 U/day,%46.7, re-initiation of oral therapy was successful [P=0.05]. There was not association between reinitiation of oral therapy and age, duration of insulin therapy, dose of insulin and BMI. This study shows reinitiation of combination oral therapy in insulin treated patients with type 2 diabetes, is most likely to be successful with a shorter duration of diabetes and lower insulin requirements

SELECTION OF CITATIONS
SEARCH DETAIL